Cargando…

Structure Kinetics Relationships and Molecular Dynamics Show Crucial Role for Heterocycle Leaving Group in Irreversible Diacylglycerol Lipase Inhibitors

[Image: see text] Drug discovery programs of covalent irreversible, mechanism-based enzyme inhibitors often focus on optimization of potency as determined by IC(50)-values in biochemical assays. These assays do not allow the characterization of the binding activity (K(i)) and reactivity (k(inact)) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Antonius P.A., van Hengst, Jacob M.A., Béquignon, Olivier J.M., Deng, Hui, van Westen, Gerard J.P., van der Stelt, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745892/
https://www.ncbi.nlm.nih.gov/pubmed/31437392
http://dx.doi.org/10.1021/acs.jmedchem.9b00686
Descripción
Sumario:[Image: see text] Drug discovery programs of covalent irreversible, mechanism-based enzyme inhibitors often focus on optimization of potency as determined by IC(50)-values in biochemical assays. These assays do not allow the characterization of the binding activity (K(i)) and reactivity (k(inact)) as individual kinetic parameters of the covalent inhibitors. Here, we report the development of a kinetic substrate assay to study the influence of the acidity (pK(a)) of heterocyclic leaving group of triazole urea derivatives as diacylglycerol lipase (DAGL)-α inhibitors. Surprisingly, we found that the reactivity of the inhibitors did not correlate with the pK(a) of the leaving group, whereas the position of the nitrogen atoms in the heterocyclic core determined to a large extent the binding activity of the inhibitor. This finding was confirmed and clarified by molecular dynamics simulations on the covalently bound Michaelis–Menten complex. A deeper understanding of the binding properties of covalent serine hydrolase inhibitors is expected to aid in the discovery and development of more selective covalent inhibitors.